ABSTRACT. Anti-tumour necrosis factor (TNF) drugs have been extensively used in non-infectious uveitis (NIU), when corticosteroids or conventional immunosuppressive drugs cannot adequately control inflammation or intolerable side-effects occur. However, systemic anti-TNF therapies are also associated with a myriad of side-effects. Therefore, intravitreal administration of anti-TNF biologics has been employed to minimize patient morbidity and systemic adverse effects, while maintaining therapeutic effectivity. We undertook a systematic review to determine evidence of efficacy and safety of intravitreal administration of anti-TNF drugs in adults with NIU. We conducted this systematic review according to the PRISMA guidelines. The protocol was registered with PROSPERO (CRD42016041946). We searched CENTRAL, MEDLINE and EMBASE, from inception to April 2017, as well as clinical trial registries and grey literature. The qualitative analysis included all studies of adult patients with a diagnosis of NIU and who received intravitreal anti-TNF drugs with a 4-week minimum follow-up. A total of 4840 references were considered for title and abstract screening. Seven full texts were screened, and five studies were considered for analysis. All studies were open-label, single-centre, prospective, non-randomized, interventional case series with a follow-up between 4 and 26 weeks, employing either adalimumab in two studies and infliximab in three. Three studies showed a treatment effect of anti-TNF intravitreal injections, while one study revealed short-term improvement and one study revealed no efficacy of anti-TNF intravitreal therapy. None of the studies reported ocular adverse effects but only two studies included electrophysiological assessment in the safety analysis and no study assessed systemic human anti-drug antibodies. The available evidence is not sufficiently robust to conclude about the clinical effectivity of intravitreal anti-TNF in NIU and so no recommendation can be made. In conclusion, intravitreal injection of anti-TNF antibodies remains a possible treatment option to be explored through robust clinical investigation.
Background
Uveitis comprises a heterogeneous group of intraocular inflammatory diseases (Jabs 2005; Levy-Clarke et al. 2014; Cordero-Coma & Sobrin 2015) . Non-infectious uveitis (NIU) is thought to result from an immune-mediated response to ocular antigens. Immune responses against ocular antigens in uveitis remain unknown, although retinal arrestin (also known as soluble antigen or S-Ag) and interphotoreceptor retinoid binding protein (IRBP) have been proposed (Mattapallil et al. 2011) . Similarly, mechanisms of disease are not fully elucidated, in part because of the heterogeneity of uveitic conditions that we categorize under the umbrella term 'NIU'. There is evidence that highlights the possibility that both autoinflammatory and autoimmune responses are operative in NIU. In particular, where activation of innate immune response leads to development of adaptive immune responses (Janssen et al. 2012; Lee et al. 2014) . Notwithstanding which pathways are at play, late complications of uveitis, such as cataract, glaucoma or chronic macular oedema can be sight threatening, (Androudi et al. 2010; Caspi 2010; Srivastava et al. 2010; Cordero-Coma & Sobrin 2015) and in developed countries, they represent one of the leading causes of blindness in the working age population (Durrani et al. 2004 ). Substantial healthcare costs, workforce absence, leave of absence and long-term disability have been associated to NIU .
Overall, the goals of NIU therapy are to reduce ocular inflammation, avoid damage to anatomical structures and prevent visual loss (Levy-Clarke et al. 2014; Cordero-Coma & Sobrin 2015) . Although corticosteroids have been the mainstay of therapy, they are often insufficient for adequate disease control, and are associated with numerous wellknown systemic and local complications (Pavesio et al. 2010; S anchez-Cano et al. 2013; Lin et al. 2014 ). When inflammation is not well controlled by corticosteroids or side-effects are unacceptable or intolerable, systemic immunomodulatory therapy (IMT) should be considered. Current IMT options comprise the biologics, such as monoclonal antibodies (mAb) and fusion proteins (Pavesio et al. 2010; Srivastava et al. 2010; Giuliari et al. 2014; Pasadhika & Rosenbaum 2014) .
Different cytokines and chemokine have been involved in the pathogenesis of uveitis and have been shown to be elevated in patients with uveitis (Carreño et al. 2016) . Tumour necrosis factor (TNF) has been the leading target for NIU biologic treatment (Nakamura et al. 1994; Dick et al. 2004; Caspi 2010; Srivastava et al. 2010; Cordero-Coma & Sobrin 2015) . As a pleiotropic and multifunctional cytokine, TNF plays a pivotal role in ocular inflammation, via reactive oxygen species, promotion of angiogenesis and breakdown of the blood-retinal barrier (BRB), being associated with the development of sightthreatening NIU-associated complications (Caspi 2006 (Caspi , 2010 Pulido et al. 2010; Shim 2011; Markomichelakis et al. 2012; Levy-Clarke et al. 2014; CorderoComa & Sobrin 2015) . Anti-TNF drugs have established efficacy in several systemic inflammatory conditions related to NIU such as Behc ßet disease (Hatemi et al. 2008) , spondyloarthritis (Zochling et al. 2006) , sarcoidosis (Maneiro et al. 2012) or juvenile idiopathic arthritis (Ostring & Singh-Grewal 2013; Kalinina Ayuso et al. 2014) . The inactivation of TNF can been achieved with mAb, such as infliximab, adalimumab, golimumab and certolizumab pegol, or with receptor fusion proteins, as etanercept (Pulido et al. 2010; Levy-Clarke et al. 2014; Cordero-Coma & Sobrin 2015) . Currently these drugs are only approved for systemic administration, and their route of administration and half-life is summarized in Table 1 (adapted from  Pascual -Camps et al. 2014) .
Although these compounds are approved for other chronic immunemediated inflammatory diseases and have shown positive results in the treatment of NIU (with variable levels of evidence and excluding etanercept), their use in NIU remains largely offlabel, with the exception of adalimumab that was recently licensed after the publication of the VISUAL I and II trials (Srivastava et al. 2010; S anchezCano et al. 2013; Levy-Clarke et al. 2014; Jaffe et al. 2016a,b; Nguyen et al. 2016a,b; Schwartzman 2016) .
Several anti-TNF-related adverse effects have been described, such as reactivation of latent tuberculosis or hepatitis B virus, invasive fungal infections, central and peripheral neuropathies, and induction of immune disturbances (Lawson et al. 2006; Pulido et al. 2010; Ma & Xu 2013; Levy-Clarke et al. 2014; Cordero-Coma & Sobrin 2015) . Side-effects related to systemic administration have led to the investigation of intravitreal route of administration, as an option that could curtail some of these unwanted effects while preserving therapeutic efficacy (Levy-Clarke et al. 2014; PascualCamps et al. 2014 ). This route of drug delivery has been well established in uveitis treated with corticosteroids (Kane et al. 2008; Taylor et al. 2012; Kempen et al. 2015a,b; Reddy et al. 2016) , anti-vascular endothelial growth factor (VEGF), (Androudi et al. 2010; Tempest-Roe et al. 2013) or sirolimus (Ibrahim et al. 2015; Vigil et al. 2015) . In experimental autoimmune uveitis, intravitreal anti-TNF administration suppresses ocular inflammation particularly inhibiting macrophage activation that suppresses structural damage and prevents functional loss. Despite no direct effect in systemic cell migration to the eye, intravitreal anti-TNF has the opportunity and experimental evidence to curtail cell activation at the target site (Khera et al. 2012) . Nonetheless, in man, intravitreal administration of anti-TNF is poorly studied, and contradictory results with respect to its efficacy and safety in NIU in both humans and animal models exist (Androudi et al. 2010; Farvardin et al. 2010; Markomichelakis et al. 2012; Arevalo et al. 2013; Tempest-Roe et al. 2013; PascualCamps et al. 2014; Khalili et al. 2016) .
The aim of this systematic review was to assess the efficacy and safety of intravitreal administration of anti-TNF drugs in adults with NIU, to discern opportunities and unmet needs. 
Materials and Methods

Protocol and registration
We conducted this systematic review and meta-analysis according to the PRISMA guidelines ). The protocol was prospectively registered with PROSPERO (registration number: CRD42016041946) and carried out according to PRISMA-P guidelines (Moher et al. 2015) .
Eligibility criteria
All studies, including case reports, case series, cohorts, case-controls and clinical trials of adult patients -aged above 18 years old -with a clinical diagnosis of persistent NIU and where patients received intravitreal anti-TNF drugs with a minimum follow-up of 4 weeks. Persistent NIU is defined as inflammation of any part of the uvea (choroid, ciliary body and/or iris) that lasts for 3 or more months, after an infectious aetiology has been excluded, or if there is a high suspicion of an immunemediated underlying mechanism, which may occur isolated or in association with a systemic condition (Jabs 2005). There were no restrictions regarding the number of participants reported in studies, year of and language of publication, publication status or aetiology of NIU.
Information sources
For the identification of studies considered for inclusion in this review, detailed search strategies were developed for each database explored: Medline (from inception to April 2017), EMBASE (from inception to April 2017) and CENTRAL (from inception to April 2017). Grey literature was retrieved from appropriate databases from inception to April 2017 (www.opengrey.eu; www.ntis. gov). Clinical trials registries (https:// clinicaltrials.gov; www.clinicaltrialsreg istry.eu) were also pursued from inception to April 2017. Non-English papers were equally assessed, translated as necessary and evaluated for inclusion. Reference lists were crosschecked, and whenever necessary, authors of published trials were contacted for further information and unpublished data.
Search
The search strategy combined (uveitis) AND (etanercept OR infliximab OR adalimumab OR golimumab OR certolizumab). The search was restricted to humans. All terms were searched as free text and as controlled vocabulary. The search strategies can be found in the Appendix S1.
Study selection
Two independent review authors (DS, IL) assessed the references identified by the search strategy, read each of the titles and abstracts of the reports and selected for inclusion the appropriate ones. If there was no abstract, the report was retrieved in full text. Then, two review authors (DS, IL) independently assessed the full-text articles for methodological quality and data extraction. Disagreements were resolved by discussion or by consensus with the participation of a third author (FBR).
Data collection process
Two review authors (DS, IL) independently extracted the data onto standardized forms and crosschecked them for accuracy. Disagreements were resolved by discussion or reached by consensus with the participation of a third author (FBR).
Data synthesis
Due to the clinical and methodological heterogeneity of the available data, the studies retrieved were only qualitatively evaluated.
Results
Before de-duplication, a total of 5675 references were considered (MED-LINE 1582, Embase 4093, CENTRAL 93). Our grey literature strategy did not retrieve any reference. One reference was retrieved by hand search (Hamza et al. 2016) . De-duplication generated 4840 references for screening. After title and abstract screening, seven studies were examined in full text. Two studies were further excluded, one due to inappropriate study design (narrative review (Yeh et al. 2012) ) and another due to wrong patient population (age-related macular degeneration (Giganti et al. 2010) ). Five studies enrolling a total of 57 patients were thus included in the final analysis: one published in 2010 (Androudi et al. 2010) , two published in 2012 (Farvardin et al. 2012; Markomichelakis et al. 2012) , one published in 2014 (Hamam et al. 2014 ) and one study published in 2016 (Hamza et al. 2016 ). We did not retrieve any unpublished studies (Fig. 1) .
Study characteristics
All studies were open-label, singlecentre, prospective, nonrandomized, interventional case series. The number of participants in each study ranged from 7 to 20. Overall, the studies enrolled a total of 66 eyes from 57 patients, based on an intention-to-treat population. All studies evaluated intravitreal injection of anti-TNF in an open-label fashion. Table 1 summarizes individuals' studies characteristics regarding anti-TNF administered drug, dose, number and scheme of injections, and duration across studies. The main inclusion criteria were patients with active NIU in all but one study - Androudi et al. 2010 ; which included patients with controlled uveitis and persistent cystoid macular oedema (CME) despite control of the inflammation. It is noteworthy that all studies bar two included patients with several aetiologies of NIU. Markomichelakis et al. (2012) and Hamza et al. (2016) exclusively included patients with ocular inflammation associated with Behc ßet disease. Table 2 describes demographic characteristics of the enrolled subjects, uveitis aetiologies, mean disease duration, possibility of concomitant conventional immunosuppressive treatment and number of patients na€ ıve to anti-TNF drugs across studies. Across all studies, age ranged from 11 to 53 years old, and 32% (n = 18) were female. All studies, except Farvardin et al. (2012) , included adult patients only. Information about the lens status in each patient was provided only in Androudi et al. (2010) . No study received industry funding.
The main outcome measures were as follows: (i) change in central macular thickness (CMT) on optical coherence tomography (OCT) in Androudi et al. (2010) ; (ii) change in best-corrected visual acuity (BCVA) and change in CMT on OCT in Hamza et al. (2016) ; (iii) change in the grade of inflammatory anterior chamber cells and vitreous haze, change in fluorescein angiography (FA) score, change in CMT on OCT and change in electrophysiological tests in Hamam et al. (2014) ; (iv) change in BCVA, change in the grade of inflammatory anterior chamber cells, vitreous haze and posterior segment in Markomichelakis et al. (2012) ; and (v) change in BCVA, change in CMT on OCT, change in vitreous haze, number of patients with retinitis, vasculitis and papilitis and change in electrophysiological tests in Hamza et al. 2016 . Tables 3 and 4 report results in each study regarding efficacy outcomes, namely number of patients with CME, mean OCT, mean CMT, mean BCVA, mean anterior chamber cells and mean vitreous haze at baseline and day 30 and the general authors' conclusion about the efficacy of the intervention.
Central macular thickness (CMT) measured by OCT significantly decreased in Markomichelakis et al. (2012) and Farvardin et al. (2012) , whereas this decrease was not significant in Androudi et al. (2010) . In Hamam et al. (2014) , only the change in median CMT between baseline and final visit (week 26) was reported, being statistically significant. About the OCT device used to assess the macula, two studies used a spectral-domain OCT device (Androudi et al. 2010 and Hamam et al. 2014) , while the other three, used a time-domain OCT device. Regarding BCVA change, in Hamza et al. (2016) , Markomichelakis et al. (2012) and Farvardin et al. (2012) , there was a significant improvement, whereas in Androudi et al. (2010) , it did not change significantly. In Hamam et al. (2014) , it is impossible to draw a similar conclusion as BCVA was only reported at baseline and 26 weeks (at 4 weeks was only the median and interquantile range are reported). Anterior chamber cells assessment according to the standardization of uveitis nomenclature (SUN) (Jabs 2005) Working Group reporting is available in Markomichelakis et al. (2012) and Hamam et al. (2014) studies. In the former, a significant decrease in this parameter between baseline and week 4 is reported, whereas in Hamam et al. (2014) , information about this parameter is only available at baseline and week 26. The vitreous haze is reported in four studies. In Markomichelakis et al. (2012), Hamam et al. (2014) and Hamza et al. (2016) , this grading was performed according to the SUN (Jabs 2005), whereas in Farvardin et al. (2012) this grading was performed according to the BIO Score (Neri et al. 2013 ). In Markomichelakis et al. (2012) , Hamza et al. (2016) and Farvardin et al. (2012) , a significant vitreous haze difference was reported between baseline and week 4. In Hamam et al. (2014) study, the progression of the median of the vitreous haze was reported to decrease significantly after 26 weeks.
Regarding concurrent IMT, in Androudi et al. (2010) study, four patients were on oral IMT (with no further specification), one patient was not under nor had history of systemic IMT and three patients had a previous history of IMT (with no further specification); in Farvardin et al. (2012) study, there is only mention to known absence of response to conventional IMT in the previous 3 months in all patients; in Hamam et al. (2014) study, prior systemic IMT and results are detailed (patient 1 has received prior azathioprine and interferon (IFN)-a-2a and had inflammation relapse, patient 2 has received prior cyclosporine A and discontinued 8 weeks after initiating intravitreal adalimumab, patient 3 had not received prior IMT and had documented inflammation relapse, patient 4 has received prior azathioprine and systemic adalimumab and had treatment failure, patient 5 has received prior azathioprine and had treatment failure, patient 6 has received prior methotrexate, IFN-a-2a and systemic with infliximab treatment failure and patient 7 received prior methotrexate, mycophenolate mofetil and azathioprine and was intolerant to conventional IMT); in Markomichelakis et al. (2012) with azathioprine and cyclosporine. In this study, a sub-analysis was performed to evaluate a possible influence of background IMT in these three subgroups of patients and statistical analysis did not reveal significant differences between the subgroups in all variables studied, including BCVA; finally in Hamza et al. (2016) study, all patients received prior azathioprine and/or cyclophosphamide and did not suspend their background treatments when entering in the study.
Safety outcomes are detailed in Tables 5 and 6 . Systemic adverse effects were not reported in any study. Only in Androudi et al. (2010) , two patients discontinued the study due to participants' preferences and one participant was lost to follow-up after the first injection. In the other four studies, there were no withdrawals independently of the reason. Only two studies reported electrophysiological assessment. No study assessed the development of anti-drug antibodies.
Taking the data together, three small observational studies (Markomichelakis et al. 2012; Hamam et al. 2014 and Hamza et al. 2016 ) showed a treatment effect of anti-TNF intravitreal injections in NIU when considering a variety of end-points that were independently chosen for each study; one small observational study (Androudi et al. 2010) showed no efficacy of anti-TNF intravitreal injections, and one (Farvardin et al. 2012 ) found a short-term improvement in ocular inflammation with anti-TNF intravitreal injections. Finally, although a systematic review was performed according to PRISMA (The Prisma Group from Moher D et al. 2009; Moher et al. 2015) and Cochrane (Higgins & Green 2011) standards, we classified the level of evidence found as 3a according to Oxford Center for Evidence-Based Medicine 2011 Levels of Evidence (OCEBM Levels of Evidence Working Group 2011) and no randomized controlled trials were retrieved in our search.
Discussion
Rationale for intravitreal administration of anti-TNF drugs Anti-TNF drugs are widely used in several systemic immune-mediated conditions such as spondyloarthritis, rheumatoid arthritis and inflammatory bowel disease (Markomichelakis et al. 2012) . Specifically, adalimumab is a recombinant human IgG1 monoclonal antibody specific for human TNF that blocks this molecule via an interaction with the p55 and p75 cell-surface TNF receptors (Neri et al. 2010 (Neri et al. , 2011 LevyClarke et al. 2014) . Infliximab is a monoclonal, chimeric (mouse/human) IgG1 j antibody that binds to the soluble and transmembrane forms of TNF (Suhler et al. 2005; CorderoComa & Sobrin 2015) . Firstly, the recently published VISUAL trials have provided level 1 evidence supporting the clinical efficacy of subcutaneous adalimumab in controlling inflammation and reducing the frequency of flares with a diverse range of uveitic diagnosis (Jaffe et al. 2016a,b; Nguyen et al. 2016a,b) . Although not formally approved for NIU, there are an important number of studies with infliximab specifically in two underlying conditions: Behc ßet disease and juvenile idiopathic arthritis (Levy-Clarke et al. 2014; Cordero-Coma & Sobrin 2015) . Moreover, evidence of the efficacy and safety of adalimumab and infliximab in adult NIU may also be found in case reports (Leccese et al. 2011; Takase et al. 2011; Zmuda et al. 2013; Capote et al. 2014; Ermetcan et al. 2014; Achille et al. 2016; Sakurai et al. 2016) , retrospective case series (Mushtaq et al. 2007; Sobrin et al. 2007; Handa et al. 2011; Okada et al. 2012; Al Rashidi et al. 2013; Dobner et al. 2013; Alfawaz et al. 2014; van Denderen et al. 2014; Interlandi et al. 2014; Kruh et al. 2014; Takeuchi et al. 2014; Kim et al. 2016; Vallet et al. 2016; Durrani et al. 2017 ) and prospective case series (Joseph et al. 2003; DiazLlopis et al. 2008; Rudwaleit et al. 2009; Suhler et al. 2009 Suhler et al. , 2013 D ıaz-Llopis et al. 2012; Erckens et al. 2012) .
Secondly, systemic TNF blockade can cause adverse events such as serious infections (notably tuberculosis reactivation), heart failure exacerbation and demyelinating disease (LevyClarke et al. 2014; Nanau & Neuman 2014; Cordero-Coma & Sobrin 2015) . Local treatment of uveitis remains useful, namely with steroids in both adult (Kane et al. 2008; Lowder et al. 2011; Tempest-Roe et al. 2013; Zarranz-Ventura et al. 2014; Holbrook et al. 2015; Kempen et al. 2015a,b; Reddy et al. 2016 ) and paediatric uveitis (Taylor et al. 2012; . Thus, the possibility to administer these drugs directly into the eye may minimize systemic adverse effects of anti-TNF drugs, while achieving local therapeutic concentrations (Androudi et al. 2010; Farvardin et al. 2010; Markomichelakis et al. 2012; Hamam et al. 2014) . In support, intravitreal anti-TNF administration has been studied in animal models with variable effects regarding efficacy and retinal toxicity (Giansanti et al. 2008; Theodossiadis et al. 2009; Tsilimbaris et al. 2009; Manzano et al. 2011; Melo et al. 2012; Yuksel et al. 2014) . The aim of the five studies included in our systematic review was to evaluate the safety and efficacy of intravitreal injections of anti-TNF drugs.
Although not fully understood, one pivotal purported mechanism in idiopathic NIU is activation and expansion of retinal antigen-specific CD4+ T lymphocytes and elaboration of nonspecific innate immune responses (Kerr et al. 2008; Khera et al. 2012; Lee et al. 2014) . Also, high levels of the cytokine TNF in the aqueous humour of patients with NIU have been described in literature (Sijssens et al. 2007; Kuiper et al. 2011) . Thus, the inceptive rational for the intravitreal use of anti-TNF drugs is based on the efficacy of these drugs in NIU when used systemically (Suhler et al. 2005; Interlandi et al. 2014; Lin et al. 2014; Vallet et al. 2016; Durrani et al. 2017 ) and the capability to rapidly reach therapeutic drug levels in the eye when used intravitreally (Modorati & Miserocchi 2012) . One reason that may explain the lack of efficacy or long-term efficacy in some of the studies is that their mechanisms of action may not be effective when administered locally in the eye, given the systemic nature of the diseases underlying the inflammatory process (Suhler et al. 2005; Tempest-Roe et al. 2013; Jaffe et al. 2016a,b; Nguyen et al. 2016a,b) . Indeed, even in specific uveitic conditions with inflammation classically confined to the eye, such as birdshot chorioretinopathy, a systemic immune deviation has been shown (Kuiper et al. 2011; Yang & Foster 2013; Lee et al. 2014; Daien et al. 2017) . In future, the combination of local and systemic anti-TNF therapy may be a reality to achieve optimal control of inflammation in NIU, alongside a more favourable safety profile (Khera et al. 2012; Lee et al. 2014 ).
Summary of evidence
In four of the five included studies, although not long-lasting, a favourable outcome in terms of anatomy and function is reported. In Androudi et al. (2010) , intravitreal adalimumab showed no efficacy in improving BCVA or decreasing CMT; however, it should be noted that in this particular study, all patients had refractory CME at baseline. Uveitic CME is thought to result from increased vascular permeability due to the breakdown of BRB and is a major risk factor for vision loss (Fardeau et al. 2015; Goldhardt & Rosen 2016) and often difficult to manage (Androudi et al. 2010; Fardeau et al. 2015; Deuter et al. 2016; Goldhardt & Rosen 2016) . As longstanding CME will result in irreversible damage to as a result of outer retinal and photoreceptor damage, anatomical resolution of the CME will not lead to improvement in BCVA (Androudi et al. 2010) . Notwithstanding this fact, in this study, the change in CMT with intravitreal adalimumab from baseline to the end of follow-up was not significant, a finding that may in part be explained by the small sample size.
In the five included studies, there were no ocular adverse effects reported, although safety assessment was limited.
Safety monitoring
With intravitreal administration, safety concerns have been raised by the experience of the use of anti-TNF in other ocular non-inflammatory conditions (Yuksel et al. 2014) . Specifically, infliximab injections may be both retinotoxic (documented with electrophysiology) (Giganti et al. 2010 ) and immunogenic (Giganti et al. 2010; Wu et al. 2011 ). Only Hamza et al. (2016) and Hamam et al. (2014) included electrophysiological assessment, and their limited data showed that intravitreal infliximab and adalimumab, respectively, were not toxic. Another main concern with intravitreal anti-TNF is the potential immunogenicity, an adverse effect that has been reported in studies with intravitreal anti-TNF for non-uveitic conditions (Theodossiadis et al. 2009; Arias et al. 2010; Giganti et al. 2010; 
<0.001
Hamam et al. Semeraro et al. 2013) . None of the studies reported here demonstrated immunogenicity. However, in uveitic eyes, an immunogenic reaction or change in pattern of the pre-existent inflammation is difficult to assess (He et al. 2013) . No study assessed systemic human anti-drug antibody responses. As such we are limited in concluding on the extent of immunogenicity following intravitreal administration in inflamed eyes.
Need for repeated injections
In Hamza et al. (2016) study, a need for repeated injection was inferred as a result because of deterioration in BCVA and increased vitreous haze between week 4 and 6. Markomichelakis et al. (2012) study recommends that repeated intravitreal versus intravenous administration of infliximab should be trialled (Markomichelakis et al. 2012) . Farvardin et al. (2012) proposes that the beneficial effect of intravitreal infliximab is not long lasting and, therefore, multiple injections may be required to achieve optimal inflammation control (Farvardin et al. 2012) , similarly to the current systemic treatment protocol with adalimumab or infliximab (Mushtaq et al. 2007; Suhler et al. 2009; Jaffe et al. 2016a,a,b,b) .
Limitations and unmet needs
Study designs were disparate across studies, namely regarding the anti-TNF drug used and the concentration and number of injections administered. Baseline population characteristics also presented differences, especially with respect to uveitis aetiology. In addition, the OCT device used to image and measure CMT was different across studies contributing to differences that have been acknowledged regarding retinal thickness analysis and segmentation algorithms in the several studies (Mylonas et al. 2009 ). The fact that concurrent/prior IMT is detailed only in three of five studies is a limitation in the interpretation these studies. We therefore emphasize the importance of specifically reporting these data, to draw more accurate conclusions of studies evaluating treatment outcomes in uveitis. Finally, all studies had a small sample size. Further well-conducted and properly sized randomized controlled trials are needed to ascertain the effects of intravitreal anti-TNF drugs in NIU. Future studies should provide more robust and fast evidence of efficacy as well as determine intravitreal half-life and toxic effects (Androudi et al. 2010) . Following this step, and depending on the nature of the results, comparative, well-designed and adequately powered, randomized clinical trials should be sought (Pulido et al. 2010) .
Conclusions
Overall, the evidence is not sufficiently robust to conclude about the efficacy of intravitreal anti-TNF in chronic NIU (i.e. any estimate of the effect is very uncertain (Atkins et al. 2004) ). The analysed studies could not be directly compared or meta-analysed due to fundamental heterogeneity in study design, inclusion criteria, doses and schema of drug administration, and end-points. The authors conclude that no recommendation can be made and that intravitreal injection of anti-TNF antibodies remains a treatment possibility still to be adequately explored.
